Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices?

Experimental and Toxicologic Pathology

Volumn 54, Issue 5-6, 2003, Pages 375-379

  Balogh, Annegret ^a   Merkel, Ute ^a   Müller, Dieter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

In vitro testing; Interaction; Liver slices; Mycophenolic acid; Niflumic acid; Tacrolimus; Xipamide

Indexed keywords

ANTIINFLAMMATORY AGENT; MYCOPHENOLIC ACID; NIFLUMIC ACID; TACROLIMUS; XIPAMIDE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIVER MICROSOME; LIVER SLICE; MALE; NONHUMAN; PILOT STUDY; RAT;

ANIMALIA;

EID: 0037559414     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00273     Document Type: Article

References (33)

1. ALLISON AC, EUGUI EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug mycophenolate mofetil. Immunol Rev 1993; 163: 5-28.
2. BALOGH A, MERKEL U, LINDNER S, et al.: Effect of xipamide on the pre-dose level of mycophenolic acid and its glucuronide metabolite. Naunyn Schiedeberg's Arch Pharmacol 2002; 365: 417.
3. BULLINGHAM R, NICHOLLS A, HALE M, et al.: Pharmacokinetics of mycophenolate mofetil (RS 61443): a short review: Transplant Proc 1996a; 28: 925-929.
4. BULLINGHAM R, SHAH J, GOLDBLUM R, et al.: Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996b; 41: 513-516.
5. FILLER G, ZIMMERING M, MAI I: Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunsuppression. Pediatr Nephrol 2000; 14: 100-104.
6. GLANEMANN M, KLUPP J, LANGREHR JM, et al.: Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunsuppressive therapy after liver transplantation. Transplant Proc 2001; 33: 1069-1070.
7. GLÖCKNER R, KUHN U, ROST M, et al.: Metabolism of model xenobiotics in human liver slices. Nova Acta Leopoldina 2003a; 87: 163-169.
8. GLÖCKNER R, WAGENER J, LIEDER A, et al.: In vitro induction of cytochrome P4503A1-mRNA and testosterone hydroxylation in precision-cut liver slices from male and female rats. Exp Toxic Pathol 2003b; 54: 411-415.
9. HALE MD, NICHOLLS AJ, BULLINGHAM RE, et al.: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672-683.
10. HEMPELMANN FW, DIEKER P: Studies on xipamide (4-chloro5-sulfamoyl-2′,6′-salicyloxylidide). Part 2: Pharmacokinetics in man. Arzneimittelforschung 1977; 27: 2143-2151.
11. HÜBNER GI, EISMANN R, SZIEGOLEIT W: Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999; 21: 536-539.
12. JAIN A, VENKATARAMANAN R, HAMAD IS, et al.: Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001; 41: 268-276.
13. JENKE A, RENNER U, RICHTE M, et al.: Pharmacokinetics of intravenous mycophenolate mofetil after allogenic blood stem cell transplantation. Clin Transplant 2001; 15: 176-184.
14. KNAUF H, MUTSCHLER E: Pharmacodynamics and pharmacokinetics of xipamide in patients with normal and impaired kidney function. Eur J Clin Pharmacol 1984; 26: 513-520
15. KUHN UD, ROST M, MÜLLER D: Para-nitrophenol glucuronidation and sulfation in rat and human liver slices. Exp Tox Pathol 2001; 53: 81-87.
16. LANGMAN LJ, LEGATT D, YATSCOFF RW: Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995; 41: 295-299.
17. LERCHE-LANGRAND C, TOUTAIN HJ: Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 2000; 153: 221-253.
18. MACKENZIE PI: Identification of uridine diphosphate glucuronosyl-transferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 2000; 22: 10-13.
19. MOURAD M, WALLEMACQ P, KONIG J, et al.: Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet 2002; 41: 319-327.
20. MÜLLER D, GLÖCKNER R, ROST M, et al.: Monooxygenation, cytochrome P450-mRNA expression and other functions in precision-cut rat liver slices. Exp Toxic Pathol 1998; 50: 507-513.
21. MÜLLER D, STEINMETZER P, PISSOWOTZKI K, et al.: Induction of cytochrome P4502B1-mRNA and pentoxyresorufin Odepentylation after exposure of precision-cut rat liver slices to phenobarbital. Toxicology 2000; 144: 93-97.
22. OELLERICH M, SHIPKOVA M, SCHÜTZ E, et al.: Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther Drug Monit 2000; 22: 20-26.
23. PARKER G, BULLINGHAM R, KAMM B, et al.: Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996; 36: 332-344.
24. PISSOWOTZKI K, GLÖCKNER R, MÜLLER D: Glucuronidation of 4-methylumbelliferone and hydroxybiphenyl and in vitro induction of UDP-glucuronidyltransferase 2B12-mRNA in precision-cut rat liver slices. Exp Toxic Pathol; (in this issue).
25. RANSOM JT: Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17: 681-684.
26. SHAW LM, KORECKA M, DENOFRIO D: Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001; 34: 17-22.
27. SHIPKOVA M, STRASSBURG CP, BRAUN F, et al.: Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001; 132: 1027-1034.
28. TSINA I, CHU F, HAMA K, et al.: Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr 1996; 675: 119-129.
29. VAN GELDER T, HILBRANDS LB, VANRENTERGHEM Y, et al.: A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266.
30. VAN GELDER T, KLUPP J, BARTEN M, et al.: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 2: 119-128.
31. VIETRI M, PIETRABISSA A, MOSCA F, et al.: Inhibition of mycophenolic acid glucuronidation by niflumic acid in human liver microsomes. Eur J Clin Pharmacol 2002; 58: 93-97.
32. VIETRI M, PIETRABISSA A, MOSCA F, et al.: Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 2000; 56: 659-664.
33. ZUCKER K, TSAROUCHA A, OLSON L, et al.: Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999; 21: 35-43